Journal article

Leopard: A Phase II Study Of Post Autologous Stem Cell Transplantation (ASCT) Maintenance Lenalidomide and Prednisolone For Myeloma (MM), Incorporating Minimal Residual Disease (MRD) Assessments

Anna Kalff, Nola Kennedy, Patricia A Walker, Marion Black, Odette Youdell, Malgorzata Gorniak, Tiffany T Khong, Lona Estifo, Angela Smiley, Anthony P Schwarer, Andrew W Roberts, Philip Campbell, Robin Flishie, Andrew Spencer

Blood | American Society of Hematology | Published : 2013


Abstract Background Despite improved outcomes achieved with high dose melphalan conditioned ASCT for MM patients, relapse is inevitable. Consolidation/maintenance therapy with novel agents following ASCT can prolong progression free (PFS) and overall survival (OS) as well as further improve depth of response, the latter being associated with superior survival. More sensitive techniques are now available to monitor minimal residual disease (MRD). Aim To document disease response changes in MM patients receiving maintenance lenalidomide and alternate-day prednisolone (RAP) af..

View full abstract

University of Melbourne Researchers